Biologics and biomarkers for asthma, urticaria, and nasal polyposis

Slides:

Advertisements

Similar presentations

D-dimer: A biomarker for antihistamine-resistant chronic urticaria

Advertisements

Monoclonal antibodies and fusion proteins in medicine

Doina M. Racila, MD, Joel N. Kline, MD, MSc

Basophils and allergic inflammation

Fatty acids, inflammation, and asthma

Endotype-driven care pathways in patients with chronic rhinosinusitis

Laurent L'homme, PhD, David Dombrowicz, PhD

Advances in food allergy in 2015

Diagnosis and management of anaphylaxis in precision medicine

Fanny Legrand, PhD, PharmD, Amy D. Klion, MD

Shyam Joshi, MD, David A. Khan, MD

Current application of exhaled nitric oxide in clinical practice

Therapeutic pipeline for atopic dermatitis: End of the drought?

Jennifer L. Ingram, PhD, Monica Kraft, MD

Biologic Therapy and Novel Molecular Targets of Severe Asthma

Is 9 more than 2 also in allergic airway inflammation?

Pavel Kolkhir, MD, Martin K

Fatty acids, inflammation, and asthma

The enigma of IgE+ B-cell memory in human subjects

Potential mechanisms for the hypothesized link between sunshine, vitamin D, and food allergy in children Milo F. Vassallo, MD, PhD, Carlos A. Camargo,

The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria Tse Wen Chang, PhD, Christina Chen, BS, Chien-Jen.

Advances in atopic dermatitis and urticarial in 2016

Immune modulation by neuronal electric shock waves

Bridging immunity and lipid metabolism by gut microbiota

Current and Future Treatment of Peanut Allergy

Ricardo U. Sorensen, MD, Luke A. Wall, MD

Time for a paradigm shift in asthma treatment: From relieving bronchospasm to controlling systemic inflammation Leif Bjermer, MD Journal of Allergy.

The Editors' Choice Journal of Allergy and Clinical Immunology

Food allergy: A review and update on epidemiology, pathogenesis, diagnosis, prevention, and management Scott H. Sicherer, MD, Hugh A. Sampson, MD Journal.

Biosimilars and drug development in allergic and immunologic diseases

Update on the role of prostaglandins in allergic lung inflammation: Separating friends from foes, harder than you might think Martin L. Moore, PhD, R.

The role of the T cell in asthma

What is an “eosinophilic phenotype” of asthma?

Weiguo Chen, PhD, Gurjit K. Khurana Hershey, MD, PhD

Cephalosporin Side Chain Cross-reactivity

Liam O’Mahony, PhD, Mübeccel Akdis, MD, PhD, Cezmi A. Akdis, MD

Mast cell granules: Modulating adaptive immune response remotely

H. William Kelly, PharmD Journal of Allergy and Clinical Immunology

Autophagy: Nobel Prize 2016 and allergy and asthma research

Immune response modifiers in the treatment of asthma: A PRACTALL document of the American Academy of Allergy, Asthma & Immunology and the European Academy.

IL-2– and CD25-dependent immunoregulatory mechanisms in the homeostasis of T-cell subsets Sven Létourneau, DPhil, Carsten Krieg, PhD, Giuseppe Pantaleo,

Food allergy: Epidemiology, pathogenesis, diagnosis, and treatment

Advances in the approach to the patient with food allergy

The discovery of IgE Journal of Allergy and Clinical Immunology

New pathways for itching in patients with atopic dermatitis?

Syk expression and IgE-mediated histamine release in basophils as biomarkers for predicting the clinical efficacy of omalizumab Donald W. MacGlashan,

Cagri Yildirim-Toruner, MD, Betty Diamond, MD

One step forward, 2 steps back: The enigma of preschool wheeze

Claus Bachert, MD, PhD, Luo Zhang, MD, Phillippe Gevaert, MD

Benjamin Chaigne, MD, Hervé Watier, MD, PhD

TH9 immunodeficiency in patients with hyper-IgE syndrome

Anaphylaxis Journal of Allergy and Clinical Immunology

Sonja A. Grundmann, MD, Pia B. Hemfort, MD, Thomas A

Does “autoreactivity” play a role in atopic dermatitis?

Innate immune responses to infection

An intranasal Syk-kinase inhibitor (R112) improves the symptoms of seasonal allergic rhinitis in a park environment Eli O. Meltzer, MD, Robert B. Berkowitz,

Endotoxin and the lung: Insight into the host-environment interaction

TH2 adjuvants: Implications for food allergy

Immune pathomechanism of drug hypersensitivity reactions

Asthma: The past, future, environment, and costs

Genetic regulation of IgE responses: Achilles and the tortoise

Albert Y. Wu, MD, Sanjiv Sur, MD, J. Andrew Grant, MD

Lisa A. Beck, MD, Sarbjit Saini, MD

The future of biologics: Applications for food allergy

An intranasal Syk-kinase inhibitor (R112) improves the symptoms of seasonal allergic rhinitis in a park environment Eli O. Meltzer, MD, Robert B. Berkowitz,

Natural history of cow’s milk allergy

Primary prevention of asthma and allergy

Itching as a systemic disease

Chitinases and chitinase-like proteins in TH2 inflammation and asthma

Foundations of Asthma.

Presentation transcript:

Biologics and biomarkers for asthma, urticaria, and nasal polyposis Thomas B. Casale, MD Journal of Allergy and Clinical Immunology Volume 139, Issue 5, Pages 1411-1421 (May 2017) DOI: 10.1016/j.jaci.2017.03.006 Copyright © 2017 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 1 Therapeutic targets for type 2–high inflammation in asthmatic patients. The figure shows cytokines and mediators released from epithelial and inflammatory cells acting on other cells important in the pathogenesis of asthma. The box shows biologics and their targets, which are integrated into the figure by colored cross hatches. Journal of Allergy and Clinical Immunology 2017 139, 1411-1421DOI: (10.1016/j.jaci.2017.03.006) Copyright © 2017 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 2 Mechanism of action of dupilumab. Dupilumab binds to the IL-4α chain prohibiting either IL-4 or IL-13 from binding and subsequent signaling through the STAT6 pathway. Journal of Allergy and Clinical Immunology 2017 139, 1411-1421DOI: (10.1016/j.jaci.2017.03.006) Copyright © 2017 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 3 Anti-IL-5 stategies. Reslizumab and mepolizumab bind to IL-5 whereas benralizumab binds to the IL-5α chain preventing IL-5 from binding and mediating antibody-dependent cell mediated cytotoxicity of cells bearing this receptor. Journal of Allergy and Clinical Immunology 2017 139, 1411-1421DOI: (10.1016/j.jaci.2017.03.006) Copyright © 2017 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 4 Mechanism of action of omalizumab. Omalizumab binds to free IgE forming small immune complexes which are cleared by the reticuloendothelial system. The reduction in IgE leads to decreased expression of the high affinity IgE receptor and decreased mediator release from mast cells and basophils and decreased antigen capture by dendritic cells. Journal of Allergy and Clinical Immunology 2017 139, 1411-1421DOI: (10.1016/j.jaci.2017.03.006) Copyright © 2017 American Academy of Allergy, Asthma & Immunology Terms and Conditions